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ABSTRACT  
Despite technical advancements in radiation and chemotherapy, pancreatic cancer 
remains resistant to treatment, with poor survival rates. Using both cell and animal 
models, we investigated combined radiation and chemotherapy regimens for their 
effectiveness in reducing tumor growth.  Preliminary data suggests combination therapy 
may be more efficacious than either therapy alone, reducing in vitro growth of a 
pancreatic cell line and in vivo tumor size.  Markers of angiogenesis suggest combined 
treatment may also result in a reduction in tumor vasculature.  
INTRODUCTION 
For several years now the survival and mortality rate of pancreatic cancer patients 
have remained relatively constant. [1] The American Cancer Society estimated that there 
would be 33,730 new cases of pancreatic cancer in the United States in 2006. [1] 
Although the occurrence rate is low, out of these new diagnoses there will be an 
estimated 32,300 deaths, representing the fourth most common cause of cancer mortality. 
[1] Currently, for all stages of pancreatic cancer combined, the 1-year survival rate is 
around 24%, and the overall 5-year survival rate has remained dismally poor at <5%. [1] 
Pancreatic cancer typically has a late onset of symptoms and the diagnosis usually 
comes after metastasis has already occurred. For the patients who are asymptomatic, do 
not detect the cancer at an early stage, and present with late stage disease, complete 
surgical resection remains the only curative treatment for pancreatic cancer. 
Unfortunately, only about 15%-20% of cases of pancreatic cancer are amenable to 
surgical resection at the time of diagnosis. Regrettably, only 16% of these patients have a 
5-year survival. [1] 
Of the remaining 80%-85% of patients, 45% present with metastatic disease, with 
a median survival of 3-6 months. [2] For these patients, the therapies that exist consist of 
chemotherapy and radiation. The most common therapy administered is 5FU 
(fluorouracil) or gemcitabine chemotherapy. In addition, patients can receive a 
combination treatment or chemoradiotherapy. [2] A number of studies have shown that 
both survival and palliative benefit can be improved when radiotherapy (RT) is combined 
with chemotherapy in certain types of cancer. [3] One clinical trial by Thierry was done 
on 353 patients with non small cell lung cancer. The combined chemoradiotherapy was 
able to increase the two year survival of the patients by 7%.  Other cancers have also 
shown benefits from combined chemoradiotherapy. In 2006, a clinical study was done on 
patients with advanced squamous cell carcinoma of the head and neck comparing 
radiation alone to chemoradiotherapy. The results showed that chemoradiotheray was a 
superior postoperative treatment. [4] Cervical cancer has also been shown to be reduced 
more effectively by chemoradiotherapy. A study performed in 2000 on cancer of the 
cervix showed that there was significant increased tumor shrinkage with concurrent 
chemoradiotherapy versus radiation alone. [5] However, despite refinements in RT 
techniques and the use of radiosensitizing agents (chemotherapies), pancreatic cancer 
remains a radiation-and chemotherapy-resistant disease with high rates of localized and 
metastatic failures. [2] 
 In this study a previously created L3.6pl cell line is used as a model of the 
metastatic form of the cancer. Not all cancer cells can survive in a specific environment, 
as stated by Stephen Paget in his seed and soil theory. [6] Therefore, a model was needed 
that could grow in the pancreas of mice, but also represent pancreatic metastatic cancer 
which produces lesions in the liver. To begin the creation of the pancreatic model the 
L3.6pl line was created from a COLO 357 human pancreatic adenocarcinoma cell line. In 
order to assure that the cell line would grow in the mouse pancreas and become 
metastatic, COLO 357 cells were orthotopically implanted in male athymic nude mice 
(BALB/c) pancreas and spleen. The spleen injections resulted in lesions in the liver. 
These lesions established that the cell line could survive in circulation and in the liver 
environment. These spontaneous metastases demonstrate that the cell line can effectively 
proliferate, induce angiogenesis, detach, move, invade the circulation, aggregate, and 
arrest in the liver, and produce growth factors in this environment. With the aim of 
guaranteeing that the line would repeatedly produce metastases in the pancreas of mice, 
the spontaneous metastases were removed from the mice and re-injected into the pancreas 
of another set of nude mice. The liver lesions were once again harvested and the cells 
were grown in culture and then were put through three more selection cycles of re-
injection. The final cell line was designated L3.6pl.  
This cell line’s doubling time is approximately 16 hours. It has high MMP-9 and 
MMP-2 mRNA levels. MMP-9 and MMP-2 are type IV collagenase enzymes that are 
responsible for degrading the extracellular matrix around the tumors. The detachment 
allows malignant cells from the primary tumor to detach and enter circulation. (Bruns, 
1999) In addition, the expression of E-cadherin, a cell surface glycoprotein, is low in the 
L3.6pl cell line. E-cadherin is responsible for cell to cell adhesion in the pancreatic cells, 
therefore lower amounts allow the cells to more easily detach and enter circulation. 
Interlukein 8 (IL-8) expression is also abnormally high in the L3.6pl cell line along with 
VEGF/VPF and bFGF. IL-8, VEGF/VPF, and bFGF are angiogenesis factors that can 
initiate and stimulate the growth of the vascular system around tumor sites. With 
additional circulation increased malignancy is possible. [7] All of these factors help in the 
growth of endothelial cells and circulation pathways in cancerous cells.   
In this study, we hypothesized that the use and therapeutic effects of radiation 
combined with chemotherapy can be improved by determining the optimal dose and 
schedule of these two regimens in human pancreatic cancer cells in vitro and in human 
tumors growing in the pancreas of athymic nude mice. By using in vitro testing, we 
determined the optimal dosage and schedule for chemoradiotherapy in highly aggressive 
and metastatic pancreatic cancer cells. Although we established that there is an optimal 
dose schedule for chemoradiotherapy in pancreatic cancer cells grown in vitro, we 
hypothesized that the effects may not be identical in vivo due to the microenvironment of 
the pancreas. Therefore, we undertook in vivo studies in orthotopic animal models in 
order to determine the effect of chemoradiotherapy on human pancreatic cancer growing 
in the pancreas (and spreading to the liver) of nude mice. These experiments provided 
information on the effects of the tumor microenvironment on treatment regimens. 
 
 
MATERIALS AND METHODS 
Pancreatic cancer cell lines and culture conditions. The highly metastatic human 
pancreatic cancer cell line L3.6pl [7] was obtained from Dr. Cheryl Baker, M. D. 
Anderson Cancer Center Orlando. L3.6pl was maintained in Dulbecco’s minimal 
essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2% 
sodium pyruvate, 2% L-glutamine, and a 2% penicillin-streptomycin mixture. Adherent 
monolayer cultures were maintained on polystyrene and incubated at 37oC in a mixture of 
5% carbon dioxide and 95% air. The cultures were free of Mycoplasma and the following 
pathogenic murine viruses: reovirus type 3, pneumonia virus, K virus, Theiler’s 
encephalitis virus, Sendai virus, minute virus, mouse adenovirus, mouse hepatitis virus, 
lymphocytic choriomeningitis virus, ectromelia virus, and lactate dehydrogenase virus 
(assayed by M. A. Bioproducts, Walkersville, MD).  The cultures were maintained for no 
longer than 10 weeks, or passage 12, after recovery from frozen stocks that were frozen 
from below passage 4. 
 
 
Reagents. Gemzar, Gemcitabine HCl, [2´-deoxy-2´,2´-diflurocytidine 
monohydrochloride (β-isomer)], a nucleoside analogue, (Eli Lilly Indianapolis, IN) was 
kept at room temperature and dissolved in 0.9% NaCl on the day of use. MTT assay kit, 
purchased from the ATCC (Manassas, VA), was protected from light and stored at 4oC. 
The following antibodies were used: rat anti-mouse CD31/PECAM (platelet/endothelial 
adhesion molecule)-1 (PharMingen International, San Diego, CA); rabbit anti- 
proliferative cellular nuclear antigen (PCNA) clone PC-10 (DAKO A/S, Copenhagen, 
Denmark); peroxidase-conjugated goat anti-rat IgG, and peroxidase-conjugated goat anti-
rabbit IgG (Jackson Research Laboratories, West Grove, CA). Other reagents used for 
immunohistochemical analysis included Hoechst Dye 3342 (molecular weight 615.9 
g/mole; Hoechst, Warrington, PA), stable 3,3'-diaminobenzidine (Research Genetics, 
Huntsville, AL), Gill’s hematoxylin (Sigma Chemical, St. Louis, MO), and pepsin 
(Biomeda, Foster City, CA).  The terminal deoxynucleotidyl transferase-mediated dUTP-
biotin end-labeling (TUNEL) assay was performed using a commercial apoptosis 
detection kit (Promega, Madison, WI). Polyclonal rabbit anti-VEGF/vascular 
permeability factor (Santa Cruz Biotechnology, Santa Cruz, CA), goat anti-rabbit IgG F 
(ab’)2.  Other reagents used for immunohistochemical (IHC) analysis include Hoechst 
Dye 3342 MW 615.9 (Hoechst, Warrington, PA), stable 3,3'-diaminobenzidine (DAB) 
from Research Genetics (Huntsville, AL), Gill’s hematoxylin from Sigma Chemical Co. 
(St. Louis, MO), and pepsin from Biomeda (Foster City, CA). 
 
 
Radiation. 
In vitro experiments involving ionizing radiation were conducted in 96 well plates from 
Corning Incorporated (Costar), Corning NY. The treatments were delivered at a dose rate 
of 12 Gy/min using a 6 MV photon beam from a Varian 2100c linear accelerator. Beam 
collimation was accomplished using a 1.5-cm stereotactic cone. 12 Gy was delivered 
using 1-cm tissue-equivalent bolus to optimize dose. 
Experiments involving ionizing radiation to the mice were conducted by delivering a 
dose rate of 4 Gy/min using a 6 MV photon beam from a Varian 2100c linear accelerator. 
Beam collimation was accomplished using a 1.5-cm stereotactic cone. 5 Gy was 
delivered at a depth of 5 mm in each mouse, using 1-cm tissue-equivalent bolus to 
optimize tumor dose. 
 
 
In Vitro Cytotoxicity Assay.  2 X 104 human L3.6pl cells in 200µl of 10% FBS DMEM 
were seeded into 38-mm2 wells of flat-bottomed 96-well plates and allowed to adhere 
overnight. In the first set of experiments, the spent medium was removed and the cultures 
were refed with new medium (negative control), medium containing increasing 
concentrations of gemcitabine (0-5 μm) in triplicate treatments or new medium followed 
by administration of ionizing radiation at a dose of 12 Gy/2 mins. All plates were 
immediately returned to the incubator and 24, 48 and 72 hrs later, the number of 
metabolically active cells was determined by MTT assay. In a second set of experiments, 
the medium was removed and cultures were refed with medium containing the IC50 of 
gemcitabine of .011µm with or without radiation. All plates were immediately returned to 
the incubator and 24 hr after the last treatment, the number of metabolically active cells 
was determined by MTT assay. Briefly, the cell proliferation assay was performed 
according to the protocol of the commercially available MTT assay kit (ATCC, 
Manassas, VA). 10 μl of MTT reagent was added to each well and the plates were 
returned to the incubator. After 2 hours incubation, 100 μl of detergent was added to each 
well and the plate was incubated overnight at room temperature. The conversion of MTT 
to formazan by metabolically viable cells was monitored by measuring the absorbance at 
562 nm using a BioTek ELx 808 Ultra Microplate reader (BIO-TEK instruments, Inc. 
Winnoski, VT). Cell proliferation was determined using a standard curve from 1 to 
100,000 cells. Growth inhibition was calculated from the formula: 
    Cytostasis (%) = [1-(A/B)] x 100, 
where A is the absorbance of treated cells and B is the absorbance of the control cells. 
 
 
Animals. Male athymic nude mice (NCI-nu) were purchased from the Charles River 
Laboratories (NCI-Frederick Animal Production Area, Frederick, MD). The mice were 
housed and maintained in the Ventilated/IsoCage system (Techniplast USA, Exton, PA) 
under specific pathogen-free conditions. The facilities were in accordance with current 
regulations and standards by the United States Department of Agriculture, United States 
Department of Health and Human Services, and the NIH. The mice were used in 
accordance with institutional guidelines when they were 8-12 weeks old. 
 
 
Orthotopic pancreatic injections. For in vivo injection, cells were harvested from 
subconfluent cultures by a brief (1-3 minute) treatment with 0.25% trypsin and 0.02% 
EDTA. Trypsinization was stopped with medium containing 10% FBS and the cells were 
washed and resuspended in 10% FBS DMEM. Only single-cell suspensions of greater 
than 90% viability, via trypan-blue exclusion, were used for injection.  Male nude mice 
were anesthetized with 50 mg/kg Xylazine/100 mg/kg Ketamine mix. A small left 
abdominal flank incision was made and the spleen and pancreas were exteriorized.  1x 
106 tumor cells were injected subcapsular in a region of the pancreas just beneath the 
spleen with a 27-gauge needle, 1-ml disposable syringe.  To prevent intraperitoneal 
leakage, a cotton swab was held for one minute over the site of injection. Both layers of 
the abdominal wound were closed with wound clips (Auto-clip; Clay Adams, Parsippany, 
NJ).  A successful subcapsular intrapancreatic injection of tumor cells was identified by 
the appearance of a fluid bleb without intraperitoneal leakage.  The mice were sacrificed 
when the controls became moribund (5-6 weeks) or at predetermined times for 
pharmacokinetic determinations. The size and weight of the primary pancreatic tumors, 
the incidence of regional lymph node metastasis, and the presence or absence of liver 
metastases were recorded. Histopathology confirmed the identity of disease. For IHC and 
histology staining procedures, one part of the tumor tissue was fixed in formalin and 
embedded in paraffin, and another part was embedded in OCT compound (Miles, 
Elkhart, IN), frozen rapidly in liquid nitrogen, and stored at -70oC.  
 
 
Treatment of Established Human Pancreatic Tumors with Gemcitabine and 
Radiation. Seven days after implantation of L3.6pl human pancreatic cancer cells into 
the pancreas, mice were randomized to receive one of four treatments (n= 10 mice per 
group): (1) twice-weekly intraperitoneal (i.p.) administration of vehicle solution alone 
(phosphate buffered saline (PBS); control group); (2) twice-weekly i.p. administrations of 
100 mg/kg gemcitabine; (3) once-weekly administration of radiation at 5Gy/2 min; (4) 
twice-weekly gemcitabine combined with radiation. Treatments continued for 5 weeks.  
The mice were sacrificed on day 35 and subjected to necropsy.  The volumes of the 
pancreatic tumors and the incidence of liver metastases were recorded.   
 
 
Necropsy Procedures and Histological Studies. Mice were sacrificed and their body 
weights were recorded.  Primary tumor volume (measured by caliper), weight, and 
incidence of regional (celiac or para-aortal) lymph node and liver metastases were 
recorded.  Visible liver metastases were counted with the aid of a dissecting microscope 
and recorded, and the tissues were processed for hematoxylin/eosin (H&E) staining. 
Tissue not homogenized immediately for immunoblot analysis was snap-frozen in liquid 
nitrogen and immediately stored at -80oC.  For immunohistochemical staining, a part of 
the tumor was embedded in OCT compound (Miles, Elkhart, IN), snap-frozen in liquid 
nitrogen, and stored at -80 oC.  
 
 
Immunohistochemical Analysis. Frozen tissues used for identification of 
CD31/PECAM-1 were sectioned (8-10 μm), mounted on positively charged Plus slides 
(Fisher Scientific,UK), and air-dried for 30 min.  The sections were fixed in cold acetone 
for 5 min, followed by 1:1 acetone:chloroform (vol:vol) for 5 min, and then acetone for 5 
min.  The sections were then washed with PBS and immunohistochemical staining for 
CD31 was performed as previously described [8].  A CD31-positive reaction was 
visualized by incubating the slides in stable 3,3’-diaminobenzidine (DAB) for 10-20 min.  
The sections were rinsed with distilled water, counterstained with Gill’s hematoxylin for 
1 min, and mounted with Universal Mount (Research Genetics, Huntsville, AL). Control 
samples were exposed to secondary antibody alone.   
Paraffin-embedded tissues were used for identification of PCNA. Sections (4-6 
μm thick) were mounted on positively charged Superfrost slides (Fischer Scientific, Co., 
Houston, TX) and dried overnight. Sections were deparaffinized in xylene and then 
treated with a graded series of alcohol [100, 95, and 80% ethanol (v/v) in double distilled 
H20] and rehydrated in PBS (pH 7.5) Sections were treated with 10 mM citrate buffer, pH 
6.0 and microwaved 10 min for “antigen’ retrieval.” Sections were blocked with 3% H202 
in PBS for 12 min and washed with PBS (3 x 5 min). Sections analyzed for PCNA were 
incubated with protein blocking solution containing 5% normal horse serum and 1% 
normal goat serum for 20 minutes and were then incubated with the appropriate primary 
antibody; anti-PCNA (1:100) overnight at 4ºC. A positive reaction was visualized by 
incubating the slides in stable 3,3’-diaminobenzidine (DAB) for 10-20 min. The sections 
were rinsed with distilled water, counterstained with Gill’s hematoxylin for 1 min, and 
mounted with Universal Mount (Research Genetics, Huntsville, AL). Control samples 
were exposed to secondary antibody alone.  
 Paraffin-embedded tissues were used for identification of VEGF.  Sections 
(4-6 m thick) were mounted on positively charged Superfrost slides (Fischer Scientific, 
Co, Houston, TX) and dried overnight.  Sections were deparaffinized in xylene and then 
treated with a graded series of alcohol [100, 95,and 80% ethanol (v/v) in double distilled 
H20] and rehydrated in PBS (pH 7.5).  Tissues were then treated with pepsin (Biomeda) 
for 15 min at 37ºC and washed with PBS (36).  A positive reaction was visualized by 
incubating the slides with stable 3,3’-diaminobenzidine for 10-20 min.  The sections were 
rinsed and distilled water, counterstained with Gill’s hematoxylin for 1 min., and 
mounted with Universal Mount (Research Genetics).  Control samples exposed to 
secondary antibody alone showed no specific staining. 
Immunostained sections were examined using a 40× objective (Zeiss Plan-
Neofluar) on an epifluorescence microscope equipped with narrow bandpass excitation 
filters mounted in a filter wheel (Ludl Electronic Products, Hawthorne, NY) to 
individually select for green and red fluorescence.  Images were captured using a cooled 
charge-coupled device camera (Photometrics, Tucson, AZ) and SmartCapture software 
(Digital Scientific, Cambridge, UK) on a Macintosh computer.   Images were further 
processed using Adobe Photoshop software (Adobe Systems, Mountain View, CA).  
Endothelial cells were identified by red fluorescence, and DNA fragmentation was 
detected by localized green and yellow fluorescence within the nuclei of apoptotic cells. 
Quantification of apoptotic endothelial cells was expressed as an average of the ratio of 
apoptotic endothelial cells to the total number of endothelial cells in 5–10 random 0.011-
mm
2 
fields at x 400 magnification.  
 
 
Statistical Analysis. Pancreatic tumor volumes, numbers of CD31- and PCNA-positive 
cells, and percentages of apoptotic endothelial cells were compared by the unpaired 
Student’s t test (or ANOVA).  The incidences of liver metastasis between groups were 
compared using Fisher’s exact test.  
 
 
RESULTS 
In Vitro Schedule of Chemoradiotherapy 
Through the use of MTT analysis of pancreatic cells treated with varying doses of 
gemcitabine (chemotherapy), the optimal biological dose to eliminate 50% of the viable 
cells of the L3.6pl cell line was determined. The three trials are shown in Figure 1 a,b, 
and c. The optimal dosage of gemcitabine for the 24, 48, and 72 hour trials was 0.33, 
.011, and 6.80*10^-4 µm respectively by using the logarithmic equation  for the best fit 
line from each graph as determined using Excel software package. The 72 hr gemcitabine 
(panel c) showed the most promising r- squared value; however the % control was 
stabilized at 0% at a very low does of gemcitabine. Therefore, the next best r-squared 
value was the 48 hour experiment (panel b). Therefore, in all subsequent experiments 
0.11µm gemcitabine was used. 
 
Figure 1: Gemcitabine Ic50 
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Figure 1: The cell number as a percent control versus chemotherapy concentration administered. Cell number was 
measured by MTT Assay (See Materials and Methods). Panel a is the effect on cell number of gemcitabine applied and 
measured 24 hours later. Panel b is the effect on cell number of gemcitabine applied and measured 48 hours later. Panel 
c is the effect on cell number of gemcitabine applied and measured 72 hours later. The insets of each panel represent 
the area from 0 to .2 µm gemcitabine for each time frame.   
 
Next, the most effective schedule of administration of gemcitabine combined with 
radiation was evaluated. Figure 2 is a graphic representation of the chemoradiation 
therapy trials. The Varian linear accelerator was unable to do localized radiation and 
therefore internal negative control wells could not be included on the chemoradiotherapy 
plates. The radiation is able to affect the medium in which the cells are contained by 
changing the pH, which is observed by a color change in phenol red containing medium. 
Therefore, comparing the chemoradiotherapies to a control without radiation may 
produce skewed results. In order to compare chemoradiotherapy to chemotherapy alone, 
internal control wells were kept, however they received radiation. When calculating the 
cell number as a percent control the control has received radiation and therefore the 
percent decrease is due only to the chemotherapy or the additive effect of the combined 
chemoradiotherapy. 
 
 
 
Figure 2: Schematic Representation of Chemoradiotherapy schedules 
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Figure 2: A schematic Representation of the combined chemoradiotherapy schedules. The striped boxes represent 
radiation, the white boxes represent chemotherapy, and the black boxes represent the combined therapy.   
Table 1: MTT Results represented as a percent control. Chemoradiotherapies represented as a 
percent radiation control. n=1 
Therapy Cell Number as Percent Control 
24 hr No Treatment Plate 100% 
48 hr No Treatment Plate 100% 
   
24 hr Radiation Plate 102% 
48 hr Radiation Plate 97% 
   
24 hr Chemotherapy Plate 84% 
48 hr Chemotherapy Plate 61% 
  Cell Number as Percent Radiation Control
Radiation for 24 hrs, 24 hrs Post Chemotherapy Plate 63% 
Radiation for 24 hrs, 48 hrs Post Chemotherapy Plate 14% 
   
Chemotherapy for 24 hrs, 24 hrs Post Radiation Plate 84% 
Chemotherapy for 24 hrs, 48 hrs Post Radiation Plate 63% 
 
We determined that administration of .011µM gemcitabine 48 hrs post 
administration of 12 Gy radiation caused a decrease in the cell count of human pancreatic 
cancer cells in vitro compared to chemotherapy or radiation alone (Table 1). Figure 3 is a 
comparison of the combined treatments versus the respective chemotherapy alone 
controls. The radiation for 24 hrs, 48 hrs post chemotherapy plate was omitted, because 
the chemotherapy alone control would have been 72 hours. However, a 72 hour 
chemotherapy control was not run and therefore, no comparison could be made. 
Nevertheless, prior experiments such as those in Figure 1 showed that 0.011 µm of 
chemotherapy would produce a decline in cell number by approximately 20%. Therefore, 
the 14% decrease in the combined therapy would likely not have represented a decrease 
from the potential chemotherapy alone plate. 
 
Figure 3: Comparison of Chemotherapy and Chemoradiotherapy treatments 
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Figure 3:  The cell number as a percent control of chemoradiotherapy treated cells versus chemotherapy treated cells. 
Cell number was measured by MTT Assay (See Materials and Methods) The first set of bars represent cell treated with 
radiation 24 hours post chemotherapy treatment, there was an insignificant change from the 48 hour chemotherapy 
treated cells. Bar two represents cells treated with chemotherapy 24 hours post radiation treatment, there was no change 
from the 24 hour chemotherapy treated cells. The last bar represents cells treated with chemotherapy 48 hours post 
radiation treatment, there was a 21% decrease in cell number  from the 24 hour chemotherapy treated cells. 
 
In Vivo Chemoradiotherapy Effects 
 Lastly, we evaluated the therapeutic effect of chemoradiotherapy in comparison to 
radiation and chemotherapy alone in vivo. L3.6pl cells were injected into the pancreas of 
nude mice. Seven days after injection the mice were randomized to receive one of four 
treatments: (1) twice-weekly i.p. administration of vehicle solution alone (control group); 
(2) twice-weekly i.p. administrations of 100 mg/kg gemcitabine; (3) once-weekly 
administration of radiation at 5Gy/2 min; (4) twice-weekly gemcitabine combined with 
radiation once weekly. The mice were treated for 5 weeks, sacraficed, and then 
necropsied. Results shown in Table 2.  
 
 Table 2: Necropsied Mice Pancreatic Tumor Data 
Group Body Weight (g) Tumor Weight (g) 
Tumor Volume 
(mm3) Liver Mets (%) 
Control 28.7+/- 1.4 1.2 +/- .3  249.7 +/- 90 75 
Gemcitabine 28.7+/- .8 0.78 +/- .08 135.1 +/- 18.1* 43 
Radiation 31.5+/- 1.1 0.41 +/- .12 60.3 +/- 28.5* 13 
Gem/Rad 31.3 +/- 1.4 0.27 +/- .08 20.3 +/- 10.3* 17 
*All treatments were found significantly different from the control group with a p value of < .01.  
 
Necropsy showed that there was a tumor present in the pancreas of all the mice. 
Radiation and chemotherapy treatments alone decreased the tumor volume. The 
chemoradiotherapy also showed a decrease in tumor volume. An ANOVA showed a 
significant difference among treatment groups overall. A Student-Newman-Keuls post-
hoc analysis (Table 3) showed the only significant difference was between all treatments 
and the control (p<.05).  However, the trend suggests that with larger sample sizes, 
significant differences might be observed between chemotherapy, radiation, and 
chemoradiotherapy. Therefore, further tests with larger groups are necessary. 
 
Table 3: Student-Newman-Keuls Significance Test 
 Tumor Volume 
 
  treatment N 
Mean Tumor 
Volume 
      Treatment 
Student-Newman-Keuls both 6 20.333
  radiation 8 60.250
  chemo 7 135.143
  control 4 262.250 
  Significance  0.052
Numbers shown are mean tumor volume for each treatment. 
 
Additionally, IHC analyses were performed on the four different treatment groups 
to determine PCNA, CD31 and VEGF expression. The IHC analyses of the pancreas 
tumors revealed that tumor cell proliferation, represented by the PCNA staining, was 
barely detectable in the radiation and chemoradiotherapy treated mice. However, blood 
vessel growth represented by CD31, appeared to be unaffected in the radiation group 
while the amount of staining was reduced in the combination therapy groups. This was 
consistent with the VEGF expression which was high in the radiation group and low in 
the chemoradiotherapy.  (Figure 4) 
 
Figure 4: Immunohistochemistry Analysis of Necropsied Mice Pancreatic Tumors 
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DISCUSSION 
Indeed the management of patients with locally advanced pancreatic cancer 
involves a multidisciplinary approach among the pancreatic surgeon, gastroenterologist, 
medical and radiation oncologist and the research team. The main consideration is 
whether a patient is ultimately a candidate for combined chemoradiotherapy (chemo-RT) 
or chemotherapy or radiation as a single agent.  A number of studies have shown that 
both survival and palliative benefit can be improved when radiotherapy (RT) is combined 
with chemotherapy. However, the survival benefit is still modest and local control of the 
tumor remains a significant challenge. In this pilot study, we have investigated the effect 
of chemoradiotherapy on pancreatic cancer cells. Our data provide evidence that 
chemoradiotherapy treatments may be more effective in treating metastatic pancreatic 
cancer than either radiation or chemotherapy treatments alone by reducing tumor cell 
growth and decreasing the production of VEGF, which is responsible for the growth rate 
of blood vessel vasculature.  
To determine the biological effects of varying chemoradiotherapies on cultured 
pancreatic cancer cells, we tested the treatment schedules by varying the time and 
schedule of radiation and chemotherapy administration. The cell number decrease in the 
combination therapies was calculated as a percentage of the internal control. The internal 
control on the plate received radiation, as it was not possible to administer radiation to 
only a section of the plate. Therefore, the cell number decrease was due to only the 
chemotherapy and the additive effects of the combined treatment. The only therapy that 
showed a significant change from the chemotherapy alone treatment was radiation for 48 
hours followed by chemotherapy. This finding suggests that the scheduling of treatments 
can be an important factor in cytotoxicity. Perhaps the radiation administrations had 
damaged or mutated the DNA and given the cells time to divide, and therefore the 
daughter cells were more easily targeted by the chemotherapy.  
To address whether the in vitro results would correlate to those in vivo, we 
evaluated the therapeutic effect of chemoradiotherapy in mice. Although the tumor 
volumes in the chemotherapy and chemoradiotherapy treatment groups were not 
significantly different, the extreme range in tumor size among the different treatment 
group suggests that more experiments should be performed to further investigate the 
potential effects of combined treatment regimens.  
Vasculature in tumor cells has shown a significant correlation with the ability of a 
tumor to grow and increase in size. Vascular endothelial growth factors (VEGFs), 
produced by the tumor cells, induce the tumor vasculature. Therefore, the level of VEGFs 
was determined in each treatment group to determine whether chemoradiotherapy 
treatments could have an effect on tumor vasculature. The immunohistochemistry results 
showed a reduced staining of VEGF and CD31 in response to chemoradiotherapy. CD31 
is a vasculature cell marker. There is an obvious decrease in blood vasculature in the 
chemoradiotherapy treatment groups as compared to the control and single treatment 
groups. The decrease in VEGF and vasculature in the tumors will limit the cells access to 
circulation and nutrients. Thus both tumor metastases and tumor cell growth will likely 
be limited by diminished tumor angiogenesis. This concept of anti-angiogenesis is a 
widely studied area in cancer therapies today, and this pilot study suggests that combined 
therapy regimens may contribute to anti-angiogenesis protocols. 
Despite refinements is RT techniques and the use of radiosensitizing agents 
(chemo  
 
ith 
 
therapies), pancreatic cancer remains a radiation-and chemotherapy-resistant
disease with high rates of local and distant failures. Evidently, a more effective treatment
schedule is necessary in order to extend the median survival of patients diagnosed w
pancreatic cancer. These results show that chemoradiotherapy given in optimal dosages 
may be a more effective cancer treatment than either treatment alone. The in vitro data
clearly demonstrate that different treatment schedules of chemoradiotherapy can produce 
varying results. In addition, the in vivo results provided evidence for reduced VEGFs 
levels, reduced tumor vasculature, and decreased cell proliferation in the combined 
treatment group.  
REFER
er 
ichéle Tarayre , Lacombe-Terrier Marie-José , Jean-Yves Douillard4, 
Agnés Laplanche  . Radiotherapy Alone Versus Combined Chemotherapy and 
Radiotherapy in Nonresectable Non-Small-Cell Lung Cancer: First Analysis of a 
Randomized Trial in 353 Patients. Journal of the National Cancer Institute, Vol. 83, No. 
6, 417-423, March 20, 1991 
 
[4] Winquist E, Oliver T, Gilbert R. Postoperative Chemoradiotherapy for advanced 
squamous cell carcinoma of the head and neck: A systematic review with meta-analysis.  
 
[5] Kim RY, Spencer SA. Tumor shrinkage before intracaitary brachytherapy for cancer 
of the cervix: radiotherapy alone versus concurrent chemoradiotherapy. Cancer Journal, 
2000 Nov-Dec; 6(6); 377-380.  
 
[6] Fidler, Isaiah. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis 
revisited. Nature Reviews Cancer, Vol. 3, 1-6, June 2003.  
 
[7] Bruns J. Christine, Matthew T. Harbison, Hiroki Kuniyasu, Ines Eue and Isaiah J. 
Fidler. In Vivo Selection and Characterization of Metastatic Variants from Human 
Pancreatic Adenocarcinoma by using Orthotopic Implantation in Nude Mice. Neoplasia, 
Vol 1, No. 1, April 1999, pp. 50-62.    
 
[8] Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ:  Expression of 
angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. 
J Natl Cancer Inst 90: 447-454, 1998. 
 
[9] Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana CD, Fidler IJ:  Level and 
function of epidermal growth factor receptor predict the metastatic potential of human 
colon carcinoma cells.  Clin Cancer Res 1: 19-31, 1995. 
 
[10] Burris H III, Moore M., Andersen J, Green M, Rothenberg M, Modiano M, Cripps 
M, Portenoy R, Storniolo A, Tarassoff P, Nelson R, Dorr F, Stephens C, Von Hoff D: 
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for 
patients with advanced pancreas cancer: a randomized trial.  J Clin Oncol 15: 2403–
2413, 1997. 
 
ENCES 
 
[1] American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer 
Society; 2006. 
 
[2] American Cancer Society. Cancer Facts and Figures 2005. Atlanta: American Canc
Society; 2005. 
 
[3] Thierry Le Chevalier1,*, Rodrigo Arriagada1, Elizabeth Quoix2, Pierre Ruffle1,3, 
Michel Martin3, M 1 1
1
